APLS

Apellis Pharmaceuticals, Inc. Common Stock

$0.00

+0.40%
Apr 2, 2026
Bobby Quantitative Model
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapies by inhibiting the complement system. It is a leader in targeting the C3 protein with its two marketed drugs, SYFOVRE and EMPAVELI, addressing diseases with high unmet medical needs.

People also watch

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

VRTX

Analysis
Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

REGN

Analysis
Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

ALNY

Analysis
Insmed, Inc.

Insmed, Inc.

INSM

Analysis
United Therapeutics Corp

United Therapeutics Corp

UTHR

Analysis

APLS 12-Month Price Forecast

Historical Price
Current Price $40.39
Average Target $40.39
High Target $46.448499999999996
Low Target $34.3315

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Apellis Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.

Average Target

$0.00

9 analysts

Implied Upside

vs. current price

Analyst Count

9

covering this stock

Price Range

$0 - $0

Analyst target range

Buy
2 (22%)
Hold
4 (44%)
Sell
3 (33%)

No sufficient analyst coverage available. The provided data includes analyst ratings and actions, but they are from 2024 and do not contain current target prices or a consensus rating as of the analysis date. The recent news of a major acquisition by Biogen has fundamentally altered the investment thesis, making prior analyst targets largely obsolete.

Drowning in data?

Find the real signal!

APLS Technical Analysis

The stock has exhibited extreme volatility over the past six months, culminating in a dramatic surge. The price data shows a steady decline from late 2025 through March 2026, falling from around $30 to a low near $17, followed by an explosive 135.4% single-day jump to $40.23 on March 31, 2026. This final surge is the dominant feature of the short-term performance, rendering the 1-month change of +91.94% and the 3-month change of +60.15% as artifacts of this single event rather than a sustained trend. The current price of $40.23 is at the very top of its 52-week range of $16.10 to $40.45, indicating it is trading near its annual high. No RSI data was provided for analysis of overbought or oversold conditions.

Beta

0.29

0.29x market volatility

Max Drawdown

-43.5%

Largest decline past year

52-Week Range

$16-$40

Price range past year

Annual Return

+78.1%

Cumulative gain past year

PeriodAPLS ReturnS&P 500
1m+95.1%-3.7%
3m+60.8%-4.1%
6m+69.7%-2.1%
1y+78.1%+16.1%
ytd+56.2%-3.9%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

APLS Fundamental Analysis

Revenue and profitability have been highly volatile on a quarterly basis. Q3 2025 showed strong performance with $458.6M in revenue and a net income of $215.7M, but this was followed by a significant contraction in Q4 2025 to $199.9M in revenue and a net loss of -$58.95M, representing a year-over-year revenue decline of -5.94%. The company maintains a strong current ratio of 3.14, indicating good short-term liquidity, but carries a debt-to-equity ratio of 1.31, reflecting a leveraged balance sheet. Operationally, the trailing twelve-month return on equity (ROE) is a modest 6.05%, while the latest quarterly free cash flow was negative, though the TTM figure remains positive at $45.3M.

Quarterly Revenue

$199913000.0B

2025-12

Revenue YoY Growth

-0.05%

YoY Comparison

Gross Margin

+0.85%

Latest Quarter

Free Cash Flow

$45327000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Open an Account, get $2 TSLA now!

Valuation Analysis: Is APLS Overvalued?

Given the company's inconsistent profitability, with a recent quarterly net loss, the Price-to-Sales (PS) ratio is a more appropriate valuation metric than the P/E ratio. The current PS ratio is 3.15. For peer comparison, the provided valuation data does not include industry average PS ratios, so a relative assessment cannot be made. The forward P/E is deeply negative at -130.57, reflecting expected near-term losses, and the EV/EBITDA of 45.49 is high, indicating the market is pricing in significant future growth.

PE

141.4x

Latest Quarter

vs. Historical

High-End

5-Year PE Range -30x~3x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

45.5x

Enterprise Value Multiple

Investment Risk Disclosure